🔗 Share this article

Given that the US proceeds with sweeping adjustments to its vaccine schedules, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning coronavirus vaccinations in the pandemic and has focused upon potential deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders had intended to reveal major revisions to the childhood immunization program recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a major change that would place the US at odds with many the international standard with no evidence for public health gain. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this year.

A Shift at the Agency

The acting appointment might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US in order to be more similar to the Danish model, a country with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Høeg has no obvious background in medication creation, oversight or management, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She has no expertise in pharmaceutical oversight.”

Former directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes thousands of generic drugs. There is also a biosimilars division, OTC medication office and more, and every single one need to be managed,” Dr. Woodcock said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a substantial management aspect to the role, which supervises over 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Contentious Programs

In response to concerns about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among agency officials on immunizations, a representative said that the “questions are based on flawed premises”.

“Her resume matches the responsibilities of her role,” the spokesperson said, noting the time Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's controversial expedited review system, a contentious expedited therapy clearance system that reportedly worried her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he remarked, “the FDA looks to be trending towards less stringent oversight of most medications, except for shots.”

Established History on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, track record, Howard have noted. She authored a research paper using unconfirmed crowd-sourced reports to determine the frequency of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current administration featured altering guidelines for new vaccines and discontinuing “optional” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has allegedly proposed barring young men from receiving COVID-19 vaccinations.

“She’s an all-around true believer who starts off with her conclusions and reverse-engineers to retrofit the data in a extremely deceptive, untruthful way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|